Search

everythinglearnresearchcommunity

for

Search:↓

Cancer rates are increasing in developed countries, with estrogen, aging, low vitamin D3, and HPV infection as common causes.

Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.

The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.

Accidental findings have led to new hair treatment discoveries, like using blood pressure and diabetes medications for hair loss and unwanted hair.

Telocytes help organize male reproductive tissues and their changes can lead to diseases.

Large prostates link to more hair loss.

Monascus helps prevent baldness, prostate issues, and may be a natural alternative to medications.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Liposomes improve finasteride delivery for hair loss treatment, making it a promising option for topical use.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

Male genital development is driven by androgen signaling and understanding it could help address congenital anomalies.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

A new compound was effective for imaging prostate cancer in rats.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.

A reliable, cost-effective method was developed for accurately measuring finasteride in medicines.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Suppressing certain hormones might help prevent prostate cancer.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.